Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 15;110(9):635-643.
doi: 10.1136/heartjnl-2023-323483.

The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications

Núria Mercadé-Besora  1   2   3 , Xintong Li  1 , Raivo Kolde  4 , Nhung Th Trinh  5 , Maria T Sanchez-Santos  1 , Wai Yi Man  1 , Elena Roel  3 , Carlen Reyes  3 , Antonella Delmestri  1 , Hedvig M E Nordeng  6   7 , Anneli Uusküla  8 , Talita Duarte-Salles  3   9 , Clara Prats  2 , Daniel Prieto-Alhambra  10   9 , Annika M Jödicke  1 , Martí Català  1
Affiliations

The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications

Núria Mercadé-Besora et al. Heart. .

Abstract

Objective: To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications.

Methods: We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0-30, 31-90, 91-180 and 181-365 days. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively.Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were conducted across staggered cohorts and databases.

Results: The study included 10.17 million vaccinated and 10.39 million unvaccinated people. Vaccination was associated with reduced risks of acute (30-day) and post-acute COVID-19 VTE, ATE and HF: for example, meta-analytic sHR of 0.22 (95% CI 0.17 to 0.29), 0.53 (0.44 to 0.63) and 0.45 (0.38 to 0.53), respectively, for 0-30 days after SARS-CoV-2 infection, while in the 91-180 days sHR were 0.53 (0.40 to 0.70), 0.72 (0.58 to 0.88) and 0.61 (0.51 to 0.73), respectively.

Conclusions: COVID-19 vaccination reduced the risk of post-COVID-19 cardiac and thromboembolic outcomes. These effects were more pronounced for acute COVID-19 outcomes, consistent with known reductions in disease severity following breakthrough versus unvaccinated SARS-CoV-2 infection.

Keywords: COVID-19; Electronic Health Records; Epidemiology; PUBLIC HEALTH.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study outcome design. Study outcomes of interest are defined as a COVID-19 infection followed by one of the complications in the figure, within a year after infection. Outcomes were ascertained in four different time windows after SARS-CoV-2 infection: 0–30 days (namely the acute phase), 31–90 days, 91–180 days and 181–365 days (these last three comprise the post-acute phase).
Figure 2
Figure 2
Forest plots for the effect of COVID-19 vaccines on post-COVID-19 cardiac and thromboembolic complications; meta-analysis across cohorts and databases. Dashed line represents a level of heterogeneity I2>0.4. ATE, arterial thrombosis/thromboembolism; CD+HS, cardiac diseases and haemorrhagic stroke; VTE, venous thromboembolism.
Figure 3
Figure 3
Forest plots for comparative vaccine effect (BNT162b2 vs ChAdOx1); meta-analysis across cohorts and databases. ATE, arterial thrombosis/thromboembolism; CD+HS, cardiac diseases and haemorrhagic stroke; VTE, venous thromboembolism.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Pritchard E, Matthews PC, Stoesser N, et al. . Impact of vaccination on new SARS-Cov-2 infections in the United Kingdom. Nat Med 2021;27:1370–8. 10.1038/s41591-021-01410-w - DOI - PMC - PubMed
    1. Lauring AS, Tenforde MW, Chappell JD, et al. . Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-Cov-2 variants in the United States: prospective observational study. BMJ 2022;376:e069761. 10.1136/bmj-2021-069761 - DOI - PMC - PubMed
    1. Burn E, Roel E, Pistillo A, et al. . Thrombosis and thrombocytopenia after vaccination against and infection with SARS-Cov-2 in the United Kingdom. Nat Commun 2022;13:7169. 10.1038/s41467-022-34669-9 - DOI - PMC - PubMed
    1. Li X, Burn E, Duarte-Salles T, et al. . Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different COVID-19 vaccines: international network cohort study from five European countries and the US. BMJ 2022;379:e071594. 10.1136/bmj-2022-071594 - DOI - PMC - PubMed
    1. Husby A, Hansen JV, Fosbøl E, et al. . SARS-Cov-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ 2021;375:e068665. 10.1136/bmj-2021-068665 - DOI - PMC - PubMed

Substances